| Holder | AKTS | Economics | Votes |
|---|---|---|---|
| MPM BIOIMPACT LLC | 4.8M | 8.67% | 8.97% |
| EcoR1 Capital, LLC | 4.8M | 8.65% | 8.95% |
Sign up to see all 10.
| Class | Shares outstanding | Held by institutions | Votes a share | Economics a share |
|---|---|---|---|---|
| AKTS | 53.9M | 63.3% | 1 vote | 1 |
| Class A | 1.9M | none filed | no vote | 1 |
SEC filing aktis_12.31.25_10k.htm: Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company’s stockholders provided, however, that, except as otherwise required by law, holders of common stock are not be entitled to vote on any amendment to the Company’s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of Preferred Stock if the hol...
SEC filing aktis_12.31.25_10k.htm: Our Class A common stock has no voting rights. As a result, all matters submitted to our stockholders will be decided by the vote of holders of our common stock. Based on the beneficial ownership of our common stock as of March 10, 2026, our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially owned approximately 56.2% of our out...
A trend across this company's share classes isn't available yet: each quarter's 13F filings add up shares of classes that differ in economics and votes.
Sign up to see all 5.
Sign up to see all 5.
Sign up to see all 4.
Every notice on Red Flags →A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.
There are not yet two fiscal years of reported share counts for Aktis Oncology, Inc..
| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
MB
MPM Bioimpact LLC
|
4.8M | — | Unchanged | Q1 '26 | 9.5% | |
|
Shares held by quarter
|
||||||
|
EC
EcoR1 Capital, LLC
13D · 9.1%
|
4.8M | — | Unchanged | Q1 '26 | 7.6% | |
|
Shares held by quarter
Peak holding4.8M (Q1'26)
Change over 8 quarters+4.8M
Disclosed stake13D · 9.1%
|
||||||
28 more super investors behind a free account
See every manager holding Aktis Oncology, Inc., how their position has changed, and how long they've held it.
Sign up free| Fund | Position value | Shares | % of company | % of the fund | As of |
|---|---|---|---|---|---|
|
VH
Vanguard Specialized Funds
|
$32.3M | 1.5M | — | 0.08% | July 31, 2026 |
|
TR
T. Rowe Price Small-Cap Stock Fund, Inc.
|
$21.8M | 676.6K | — | 0.23% | June 30, 2026 |
23 more funds behind a free account
See every fund holding Aktis Oncology, Inc. and how much of the fund the position is.
Sign up free| Holder | Shares | % of company | Change vs last qtr | 8 quarters | Held since | % of their book |
|---|---|---|---|---|---|---|
|
AG
Ansbert Gadicke
5%+ holder
13D · 19.3%
|
10.3M | — | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
Disclosed stake13D · 19.3%
|
||||||
|
EL
Eli Lilly and Company
5%+ holder
13D · 11.9%
|
6.3M | — | — | — |
— | — |
|
This holder reports through Schedule 13D/G, not a quarterly 13F.
Disclosed stake13D · 11.9%
|
||||||
20 more holders behind a free account
See every insider and 5%+ holder of Aktis Oncology, Inc..
Sign up freeLoading...